Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to Commission file number: 001 -40241 LAVA Therapeutics N.V. (Exact Name of Registrant as Specified in Its Charter) The Netherlands (State or Oth ...

Exhibit 99.1 LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Utrecht, The Netherlands, and Philadelphia, PA, US – March 28, 2025 – LAVA Therapeutics N.V. (NASDAQ: LVTX, "LAVA," "the Company"), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2024. "LAVA' ...

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266Phase 1 enrollment in LAVA-1266 clinical trial underwayJohnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, ...

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266Phase 1 enrollment in LAVA-1266 clinical trial underwayJohnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, ...

Core Viewpoint - LAVA Therapeutics N.V. is initiating a strategic review process aimed at maximizing shareholder value, which includes cost-cutting measures and workforce reduction [2][4][5] Financial Position - As of December 31, 2024, the company's cash balance, cash equivalents, and investments totaled $76.6 million [6] Strategic Options - The company is exploring various strategic options such as in-licensing assets, sales, licensing agreements, mergers, acquisitions, or other strategic transactions [4] - There is no set timetable for the strategic review process, and updates will only be provided once specific actions are approved by the Board [4] Workforce Reduction - LAVA is implementing a restructuring plan that includes a workforce reduction of approximately 30% to enhance cost containment and conserve cash [5] - The company anticipates incurring approximately $0.5 million in one-time costs related to this workforce reduction, primarily in Q1 2025 [5] Clinical Development - LAVA will continue its Phase 1 clinical study of LAVA-1266 for hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [2][3] - The company is also committed to supporting its partnerships with Pfizer and Johnson & Johnson [2] Leadership Statement - The CEO of LAVA expressed the company's commitment to exploring strategic opportunities to enhance shareholder value, given the current focus on a single product in clinical development and an early-stage pipeline [3]

LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1 data read-out expected by year-end 2025 UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the firs ...

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page | --- | --- | |--------------------------------------------------------------------------------------------------------|-------| | | | | Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (unaudited) | 2 | | Condensed Consolidated Interim Statements of Financial Position (unaudited) | 3 | | Condensed Consolidated Interim Statements of Changes in Equity (unau ...

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Therefore, the Zacks rating upgrade for LAVA Therapeutics basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The change in a company's future earnings potential, as refle ...

UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, "LAVA"), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. LAVA Therapeutics N.V. is a clinical-stage immuno-oncology comp ...